Merck & Co., Inc. (MRK) FCF Payout Ratio: 58.85%
Is Merck & Co., Inc.’s FCF payout ratio high or low?
Merck & Co., Inc.'s FCF payout ratio of 58.85% is 15% below its 5-year average of 68.95%, near the low end of its 5-year range (43.32%–106.71%).
The FCF payout ratio for Merck & Co., Inc. (MRK) is 58.85%. It is above its 12-month average by 7.51% (54.74%).
MRK FCF Payout Ratio Chart
MRK Average FCF Payout Ratio Chart
MRK Current vs Average FCF Payout Ratio Chart
MRK FCF Payout Ratio Metrics
FCF PAYOUT RATIO
58.85%
FCF PAYOUT RATIO AVG TTM
54.74%
FCF PAYOUT RATIO AVG 3Y
59.64%
FCF PAYOUT RATIO AVG 5Y
68.95%
FCF PAYOUT RATIO AVG 10Y
68.21%
FCF PAYOUT RATIO AVG 15Y
65.14%
FCF PAYOUT RATIO AVG 20Y
68.32%
CURRENT VS TTM AVG
+7.51%
CURRENT VS 3Y AVG
-1.33%
CURRENT VS 5Y AVG
-14.65%
CURRENT VS 10Y AVG
-13.72%
CURRENT VS 15Y AVG
-9.66%
CURRENT VS 20Y AVG
-13.87%
Payout Ratio Comparison
FCF Payout Ratio
58.9%
Earnings Payout Ratio
45.5%
Dividend Yield
2.80%
FCF Yield
4.82%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $12.36B | $8.18B | 66.1% |
| 2024 | $18.10B | $7.84B | 43.3% |
| 2023 | $9.14B | $7.45B | 81.4% |
| 2022 | $14.71B | $7.01B | 47.7% |
| 2021 | $9.66B | $6.61B | 68.4% |
| 2020 | $5.82B | $6.21B | 106.7% |
| 2019 | $9.97B | $5.70B | 57.1% |
| 2018 | $8.31B | $5.17B | 62.3% |
| 2017 | $4.56B | $5.17B | 113.2% |
| 2016 | $8.76B | $5.12B | 58.5% |
| 2015 | $11.26B | $5.12B | 45.5% |
| 2014 | $6.54B | $5.25B | 80.2% |
| 2013 | $10.11B | $5.28B | 52.2% |
| 2012 | $8.07B | $5.24B | 64.9% |
| 2011 | $10.66B | $4.81B | 45.1% |
| 2010 | $9.79B | $4.85B | 49.6% |
| 2009 | $1.93B | $3.48B | 180.1% |
| 2008 | $7.17B | $3.28B | 45.7% |
| 2007 | $5.99B | $3.31B | 55.2% |
| 2006 | $5.79B | $3.32B | 57.4% |
| 2005 | $6.21B | $3.35B | 54.0% |
| 2004 | $7.07B | $3.31B | 46.8% |
| 2003 | $7.95B | $3.25B | 40.9% |
| 2002 | $7.16B | $3.19B | 44.6% |
| 2001 | $6.36B | $3.15B | 49.5% |
| 2000 | $4.96B | $2.80B | 56.4% |
| 1999 | $3.57B | $2.59B | 72.5% |
| 1998 | $3.35B | $2.25B | 67.2% |
| 1997 | $4.87B | $2.04B | 41.9% |
| 1996 | $4.23B | $1.73B | 40.9% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Merck & Co., Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for Merck & Co., Inc. (MRK)?
- The FCF payout ratio for MRK stock is 58.85%.
- Is Merck & Co., Inc.'s FCF payout ratio high or low?
- Merck & Co., Inc.'s FCF payout ratio of 58.85% is 15% below its 5-year average of 68.95%, near the low end of its 5-year range (43.32%–106.71%).
- What is the TTM average FCF payout ratio for Merck & Co., Inc. (MRK)?
- The TTM average FCF payout ratio for MRK stock is 54.74%.
- What is the 3Y average FCF payout ratio for Merck & Co., Inc. (MRK)?
- The 3Y average FCF payout ratio for MRK stock is 59.64%.
- What is the 5Y average FCF payout ratio for Merck & Co., Inc. (MRK)?
- The 5Y average FCF payout ratio for MRK stock is 68.95%.
- What is the 10Y average FCF payout ratio for Merck & Co., Inc. (MRK)?
- The 10Y average FCF payout ratio for MRK stock is 68.21%.
- What is the 15Y average FCF payout ratio for Merck & Co., Inc. (MRK)?
- The 15Y average FCF payout ratio for MRK stock is 65.14%.
- What is the 20Y average FCF payout ratio for Merck & Co., Inc. (MRK)?
- The 20Y average FCF payout ratio for MRK stock is 68.32%.
Merck & Co., Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 66.15% |
| 2024-12-31 | 43.32% |
| 2023-12-31 | 81.43% |
| 2022-12-31 | 47.68% |
| 2021-12-31 | 68.42% |
| 2020-12-31 | 106.71% |
| 2019-12-31 | 57.14% |
| 2018-12-31 | 62.26% |
| 2017-12-31 | 113.24% |
| 2016-12-31 | 58.48% |
| 2015-12-31 | 45.46% |
| 2014-12-31 | 80.19% |
| 2013-12-31 | 52.22% |
| 2012-12-31 | 64.90% |
| 2011-12-31 | 45.13% |
| 2010-12-31 | 49.57% |
| 2009-12-31 | 180.13% |
| 2008-12-31 | 45.71% |
| 2007-12-31 | 55.23% |
| 2006-12-31 | 57.43% |
| 2005-12-31 | 53.98% |
| 2004-12-31 | 46.81% |
| 2003-12-31 | 40.90% |
| 2002-12-31 | 44.58% |
| 2001-12-31 | 49.49% |
| 2000-12-31 | 56.42% |
| 1999-12-31 | 72.54% |
| 1998-12-31 | 67.16% |
| 1997-12-31 | 41.91% |
| 1996-12-31 | 40.86% |
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis